ACE2 News and Research

RSS

SARS-CoV-2 inhibited by pyrimidine biosynthesis inhibitors in conjunction with nucleoside analogs

In an effort to hasten the research on identifying antiviral drugs for SARS-CoV-2 infection, researchers from the U.S. and Switzerland performed extensive drug screening for antiviral activity using live virus infection in human respiratory cells. As a result, they identified a set of possible drug candidates that could potentially be tested in clinical trials.

30 Jun 2021

Alpha (B.1.1.7) SARS-CoV-2 variant associated with more severe disease in hospitalized women

Researchers in the UK have conducted a study showing that infection with the B.1.1.7 (Alpha) lineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be associated with an increased risk of death or intensive care unit (ITU) admission among women, compared with non-B.1.1.7 infection.

29 Jun 2021

Cationic peptides inhibit SARS-CoV-2 cell entry

In a paper recently published in Pathogens, in silico affinity studies by researchers at the University of Illinois, USA, reveal several potential peptide binding sites required for HS-spike protein and ACE2-spike protein bond formation, and synthesis of suitable peptide inhibitors reveals impaired SARS-CoV-2 cell entry.

29 Jun 2021

Study explores structure, activity, and inhibition of TMPRSS2 implicated in SARS-CoV-2 activation

Researchers from Canada recently presented an efficient strategy for recombinant production of enzymatically active TMPRSS2 ectodomain, enabling enzymatic characterization and the 1.95 Å X-ray crystal structure. Their work is published on the bioRxiv* preprint server while awaiting peer-review.

29 Jun 2021

H69/V70 deletion in Alpha variant enables SARS-CoV-2 to overcome chinks in its armor

One of the key mutations seen in the 'Alpha variant' of SARS-CoV-2 - the deletion of two amino acids, H69/V70 - enables the virus to overcome chinks in its armor as it evolves, say an international team of scientists.

29 Jun 2021

Differences in monocyte subsets between severe COVID-19 and long COVID

Researchers in the United States and Costa Rica have identified differences in the proportions of monocyte subsets that occur in severe cases of coronavirus disease 2019 (COVID-19) following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and post-acute sequelae of COVID-19 (PASC), often referred to as “Long COVID”.

28 Jun 2021

Vaccines and drugs must be adapted to combat emerging SARS-CoV-2 variants, says study

A new review of the emerging variants of concern (VOCs) of the SARS-CoV-2, which has caused the COVID-19 pandemic, shows that there is a major need to constantly re-evaluate the utility of existing therapeutics and vaccines against the virus and to develop new ones.

28 Jun 2021

Why SARS-CoV-2 delta variant is more infectious

German experts recently explained why the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delta variant is more infectious and pathogenic than its ancestor. By conducting a series of in vitro experiments, they have revealed that increased ability to induce cell-to-cell fusion (syncytia) and reduced susceptibility to vaccine and infection-induced antibodies make the delta variant more infectious than previously circulating variants. The study is currently available on the bioRxiv* preprint server.

28 Jun 2021

Oxford study sheds light on level of antibodies needed to protect against COVID-19 symptoms

Researchers in the UK have reported on the relationship between humoral (antibody) responses and protection against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) following immunization with AstraZeneca’s ChAdOx1 vaccine.

27 Jun 2021

Lambda lineage of SARS-CoV-2 has potential to become variant of concern

Researchers have described the first reported infection with the C.37 (Lambda) lineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Southern Brazil.

27 Jun 2021

Structural studies of SARS-CoV-2 spike protein reveal new properties of Alpha and Beta variants

New SARS-CoV-2 variants are spreading rapidly, and there are fears that current COVID-19 vaccines won't protect against them.

25 Jun 2021

Novel biosensor offers rapid quantitative variant of concern-independent serology for SARS-CoV-2

Even as herculean efforts are being made to extend the reach of vaccination against COVID-19 to all the regions of the world, there is a dire need for rapid and sensitive tests to assess the antibody response to the various vaccines used and to monitor antibody titers over time. A new preprint describes a new approach to this problem which could be applied to other molecules of interest as well, both in laboratories and at the point of care.

25 Jun 2021

Study shows how SARS-CoV-2 virus enters cells to cause infection

Early in the COVID-19 pandemic, scientists identified how SARS-CoV-2, the virus that causes COVID-19, gets inside cells to cause infection.

24 Jun 2021

Scientists predict driver mutations of future SARS-CoV-2 variants of concern

A team of scientists from the USA has recently predicted the driver mutations that may appear in future variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The prediction is based on currently available genetic surveillance data on amino acid mutations present in SARS-CoV-2 variants. A detailed description of the study is currently available on the medRxiv* preprint server.

24 Jun 2021

Is COVID-19 more severe in pregnancy?

A new study, released as a preprint on the medRxiv* server, indicates that pregnant women are more likely to develop severe disease following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

24 Jun 2021

New insights can pave the way for targeted therapies to fight blood clots in COVID-19 patients

Driven by the mystery of the blood clots reported in both living and deceased COVID-19 patients, researchers from Shoolini University, India, dig deeper into the pathogenesis of COVID-19 and other similar viral diseases, looking for ways in which these clots could be formed.

24 Jun 2021

Green tea catechins might be useful as pan-coronavirus inhibitors

Scientists from the Queen’s University, Canada, have recently uncovered the broad-spectrum antiviral activity of epigallocatechin gallate, a bioactive compound from green tea, against highly pathogenic coronaviruses found in humans and animals. The compound prevents viral infection by interfering with virus-host cell attachment. The study is currently available on the bioRxiv* preprint server.

24 Jun 2021

ACE2 News and Research

SARS-CoV-2 inhibited by pyrimidine biosynthesis inhibitors in conjunction with nucleoside analogs

Alpha (B.1.1.7) SARS-CoV-2 variant associated with more severe disease in hospitalized women

Cationic peptides inhibit SARS-CoV-2 cell entry

Study explores structure, activity, and inhibition of TMPRSS2 implicated in SARS-CoV-2 activation

H69/V70 deletion in Alpha variant enables SARS-CoV-2 to overcome chinks in its armor

Differences in monocyte subsets between severe COVID-19 and long COVID

Vaccines and drugs must be adapted to combat emerging SARS-CoV-2 variants, says study

Why SARS-CoV-2 delta variant is more infectious

Oxford study sheds light on level of antibodies needed to protect against COVID-19 symptoms

Lambda lineage of SARS-CoV-2 has potential to become variant of concern

Structural studies of SARS-CoV-2 spike protein reveal new properties of Alpha and Beta variants

Novel biosensor offers rapid quantitative variant of concern-independent serology for SARS-CoV-2

Study shows how SARS-CoV-2 virus enters cells to cause infection

Scientists predict driver mutations of future SARS-CoV-2 variants of concern

Is COVID-19 more severe in pregnancy?

New insights can pave the way for targeted therapies to fight blood clots in COVID-19 patients

Green tea catechins might be useful as pan-coronavirus inhibitors

Bivalent DNA SARS-CoV-2 vaccine induces strong humoral and cellular immunity in mice

Increased severity of COVID-19 in pregnancy

SARS-CoV-2 infection and transmission in the North American deer mouse

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News